Venous thromboembolism in 2013: The advent of the novel oral anticoagulants


New findings published in 2013 strongly support the use of novel oral anticoagulants in the treatment of thromboembolic disorders. These drugs have been shown to have a more-favourable benefit-to-risk profile than older compounds, enabling their use from the start of treatment and in the whole spectrum of clinical presentations. 
DOI: 10.1038/nrcardio.2013.210


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.